News | May 25, 2026
Anupam Rasayan to acquire 43.3%–48.2% equity stake in Bliss GVS Pharma
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
Revenue from operations climbed 13% to Rs. 886.87 crore
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Pharma veteran with over three decades of industry experience to lead Alembic’s animal health growth and market expansion initiatives.
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
